{"context":{"query":">>mondo>>gwas_study","source_dataset":"mondo","target_dataset":"gwas_study"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0005180,73,MONDO:0005180,56,1]["},"schema":"id|disease_trait|first_author|journal|publication_date","mappings":[{"input":"MONDO:0005180","source":"MONDO:0005180|Parkinson disease","targets":["GCST000002|Parkinson's disease|Maraganore DM|Am J Hum Genet|2005-09-09","GCST000005|Parkinson's disease|Fung HC|Lancet Neurol|2006-09-28","GCST000261|Parkinson's disease (familial)|Pankratz N|Hum Genet|2008-11-06","GCST000528|Parkinson's disease|Simon-Sanchez J|Nat Genet|2009-11-15","GCST000530|Parkinson's disease|Satake W|Nat Genet|2009-11-15","GCST000567|Parkinson's disease|Edwards TL|Ann Hum Genet|2010-01-13","GCST000772|Parkinson's disease|Hamza TH|Nat Genet|2010-08-15","GCST000855|Parkinson's disease|Spencer CC|Hum Mol Genet|2010-11-02","GCST000874|Parkinson's disease|Saad M|Hum Mol Genet|2010-11-17","GCST000950|Parkinson's disease|Simon-Sanchez J|Eur J Hum Genet|2011-01-19","GCST000959|Parkinson's disease|Nalls MA|Lancet|2011-02-01","GCST001126|Parkinson's disease|Do CB|PLoS Genet|2011-06-23","GCST001189|Parkinson's disease|Liu X|BMC Med Genet|2011-08-03","GCST001205|Parkinson's disease (coffee consumption interaction)|Hamza TH|PLoS Genet|2011-08-18","GCST001430|Parkinson's disease|Pankratz N|Ann Neurol|2012-03-01","GCST001445|Parkinson's disease|Lill CM|PLoS Genet|2012-03-15","GCST001546|Parkinson's disease (motor and cognition)|Chung SJ|Parkinsonism Relat Disord|2012-05-30","GCST001617|Parkinson's disease|Hernandez DG|PLoS One|2012-07-24","GCST002077|Parkinson's disease|Davis MF|Hum Genet|2013-06-21","GCST002353|Parkinson's disease|Hill-Burns EM|BMC Genomics|2014-02-10","GCST002455|Parkinson's disease|Vacic V|Hum Mol Genet|2014-05-19","GCST002544|Parkinson's disease|Nalls MA|Nat Genet|2014-07-27","GCST002778|Parkinson disease and lewy body pathology|Beecham GW|Neurology|2015-02-06","GCST003059|Parkinson's disease|Hu Y|Mol Neurobiol|2015-07-31","GCST003600|Parkinson's disease (pesticide exposure interaction)|Biernacka JM|Parkinsonism Relat Disord|2016-08-03","GCST003922|Parkinson's disease|Foo JN|Hum Mol Genet|2016-12-22","GCST003984|Parkinson's disease|Pickrell JK|Nat Genet|2016-05-16","GCST004902|Parkinson's disease|Chang D|Nat Genet|2017-09-11","GCST005548|Parkinson's disease|Nalls MA|Mov Disord|2015-08-13","GCST006153|Parkinsonism in frontotemporal lobe dementia|Pottier C|Lancet Neurol|2018-04-30","GCST007198|Parkinson's disease (age at diagnosis)|Wallen ZD|Neurol Genet|2018-10-05","GCST008910|Multiple traits (pleiotropy)|Trochet H|Genet Epidemiol|2019-03-28","GCST009324|Parkinson's disease|Nalls MA|Lancet Neurol|2019-12-01","GCST009325|Parkinson's disease or first degree relation to individual with Parkinson's disease|Nalls MA|Lancet Neurol|2019-12-01","GCST009373|Parkinson's disease in GBA mutation carriers|Blauwendraat C|Brain|2019-11-22","GCST009512|Parkinson's disease|Bandres-Ciga S|Mov Disord|2019-10-29","GCST010049|Parkinson's disease|Foo JN|JAMA Neurol|2020-04-20","GCST010765|Parkinson's disease (time to event)|Bi W|Am J Hum Genet|2020-06-23","GCST010990|Parkinson's disease or schizophrenia|Smeland OB|Biol Psychiatry|2020-02-08","GCST010991|Parkinson's disease|Smeland OB|Biol Psychiatry|2020-02-08","GCST011037|Parkinson's disease progression (cognitive)|Tan MMX|Mov Disord|2020-10-28","GCST011038|Parkinson's disease progression (motor)|Tan MMX|Mov Disord|2020-10-28","GCST011039|Parkinson's disease progression (composite)|Tan MMX|Mov Disord|2020-10-28","GCST012431|Parkinson's disease|Rodrigo LM|Genes (Basel)|2021-05-04","GCST90000014|Parkinson's disease motor subtype (tremor dominant vs postural instability/gait difficulty)|Alfradique-Dunham I|Neurol Genet|2021-01-28","GCST90018674|Parkinson's disease|Sakaue S|Nat Genet|2021-09-30","GCST90018894|Parkinson's disease|Sakaue S|Nat Genet|2021-09-30","GCST90026456|Parkinson's disease|Loesch DP|Ann Neurol|2021-07-06","GCST90042668|Illnesses of father: Parkinson's disease (UKB data field 20107_11)|Jiang L|Nat Genet|2021-11-04","GCST90042681|Illnesses of mother: Parkinson's disease (UKB data field 20110_11)|Jiang L|Nat Genet|2021-11-04","GCST90042694|Illnesses of siblings: Parkinson's disease (UKB data field 20111_11)|Jiang L|Nat Genet|2021-11-04","GCST90043734|Parkinson's disease (PheCode 332)|Jiang L|Nat Genet|2021-11-04","GCST90077741|Parkinsons disease|Backman JD|Nature|2021-10-18","GCST90077742|ICD10 G20: parkinsons disease|Backman JD|Nature|2021-10-18","GCST90079817|ICD10 G20: Parkinson's disease|Backman JD|Nature|2021-10-18","GCST90081727|Parkinsons disease (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90081728|ICD10 G20: parkinsons disease (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90083803|ICD10 G20: Parkinson's disease (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90095083|Parkinson's disease|Brolin K|J Parkinsons Dis|2021-11-07","GCST90104085|Parkinson's disease|Le Guen Y|Ann Neurol|2021-03-06","GCST90104086|Parkinson's disease|Le Guen Y|Ann Neurol|2021-03-06","GCST90104087|Parkinson's disease|Le Guen Y|Ann Neurol|2021-03-06","GCST90246062|ICD10 G20: parkinsons disease|Walters RG|Cell Genom|2023-07-20","GCST90256604|Parkinson disease (MTAG)|Tirozzi A|Cells|2023-01-06","GCST90270129|Parkinson’s disease progression to dementia|Real R|Brain|2022-11-09","GCST90270939|Parkinson's disease|Pan H|NPJ Parkinsons Dis|2023-02-09","GCST90275127|Parkinson's disease|Kim JJ|Nat Genet|2023-12-28","GCST90278092|Parkinson's disease|Park KW|NPJ Parkinsons Dis|2023-10-07","GCST90296432|Parkinson's disease|Park KW|NPJ Parkinsons Dis|2023-10-07","GCST90296433|Parkinson's disease|Park KW|NPJ Parkinsons Dis|2023-10-07","GCST90297582|ICD10 G20: Parkinson's disease (CNV mirror model)|Auwerx C|Genome Med|2024-01-08","GCST90297636|ICD10 G20: Parkinson's disease (CNV U-shape model)|Auwerx C|Genome Med|2024-01-08","GCST90297732|ICD10 G20: Parkinson's disease (CNV deletion-only model)|Auwerx C|Genome Med|2024-01-08","GCST90308590|Parkinson's disease|Kim JJ|Nat Genet|2023-12-28","GCST90319903|Parkinson's disease|Doostparast Torshizi A|Nat Commun|2024-07-31","GCST90320240|Parkinson's disease|Andrews SV|Mov Disord|2023-11-28","GCST90320242|Parkinson's disease|Rizig M|Lancet Neurol|2023-08-23","GCST90321081|Parkinson disease axial motor progression|Martinez Carrasco A|Neurol Genet|2023-08-08","GCST90321082|Parkinson disease limb motor progression|Martinez Carrasco A|Neurol Genet|2023-08-08","GCST90321083|Parkinson disease motor progression|Martinez Carrasco A|Neurol Genet|2023-08-08","GCST90321084|Parkinson disease axial motor severity|Martinez Carrasco A|Neurol Genet|2023-08-08","GCST90321085|Parkinson disease limb motor severity|Martinez Carrasco A|Neurol Genet|2023-08-08","GCST90321086|Parkinson disease motor severity|Martinez Carrasco A|Neurol Genet|2023-08-08","GCST90428733|Parkinson disease|Rahman MA|Front Genet|2023-09-29","GCST90435905|Parkinson's disease (PheCode 332)|Zhou W|Nat Genet|2018-08-13","GCST90455618|Parkinson's disease|Doostparast Torshizi A|Nat Commun|2024-07-31","GCST90473307|ICD10 G20: Parkinson's disease|UK Biobank Whole-Genome Sequencing Consortium|Nature|2025-08-06","GCST90475830|Parkinson's disease|Verma A|Science|2024-07-19","GCST90476961|Parkinson's disease|Verma A|Science|2024-07-19","GCST90476962|Takes medication for parkinson's disease?|Verma A|Science|2024-07-19","GCST90477508|Parkinson's disease|Verma A|Science|2024-07-19","GCST90477509|Parkinson's disease|Verma A|Science|2024-07-19","GCST90479726|Takes medication for parkinson's disease?|Verma A|Science|2024-07-19","GCST90479727|Parkinson's disease|Verma A|Science|2024-07-19","GCST90480008|Parkinson's disease|Verma A|Science|2024-07-19","GCST90481400|Parkinson's disease|Verma A|Science|2024-07-19","GCST90481401|Parkinson's disease|Verma A|Science|2024-07-19","GCST90481402|Takes medication for parkinson's disease?|Verma A|Science|2024-07-19","GCST90481403|Takes medication for parkinson's disease?|Verma A|Science|2024-07-19","GCST90651411|Parkinson's disease (PheCode 332)|Liu TY|Sci Adv|2025-06-04"]}]}